Clinical trial · no report yet · Phase 3
KRASCENDO 3
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- NCT07541170 ↗
- Recruiting
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Divarasib; Pembrolizumab; Nivolumab
- Arms
- Divarasib · Experimental
- Control: Pembrolizumab or Nivolumab or Observation · Active comparator
- Enrollment
- 400 (estimated)
- Primary outcomes
- Disease-free Survival (DFS), as Determined by the Investigator
- Sponsor
- Hoffmann-La Roche
- Start
- Oct 6, 2026
- Primary completion
- Jan 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT07541170 · updated Oct 13, 2026